Realtime Diagnosis From Electrocardiogram Artificial Intelligence-Guided Screening for Atrial Fibrillation With Long Follow-Up (REGAL)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Had a 10-second 12-lead ECG done at Mayo Clinic
- Have a high AI-ECG risk score indicating a high likelihood of previously unrecognized AF
- Men with CHA2DS2-VASc2 ≥2 or women with CHA2DS2-VASc ≥ 3
Exclusion Criteria:
- Diagnosed atrial fibrillation
- Diagnosed dementia
- Diagnosed end-stage kidney disease
- History of intracranial bleeding
- Have an implantable cardiac monitoring device, including a pacemaker, a defibrillator, or implanted loop recorder
- Missing date of birth
- Residence outside of the U.S. or missing address information
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Apple Watch Intervention Group
Participants will be asked to wear an Apple Watch and use the Mayo Clinic ECG Study App to collect and share data with the study team.
|
Apple Watch
|
|
No Intervention: Control Group
Participants will receive usual care.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Atrial fibrillation
Time Frame: 2 years
|
Number of participants diagnosed with atrial fibrillation
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in individuals' maximum learning span
Time Frame: Baseline, 2 years
|
Measured using the Mayo Test Drive (MTD):Test Development through Rapid Iteration, Validation and Expansion.
A web-based platform for remote self-administered cognitive assessment that uses the Stricker Learning Span (SLS), which is a computer adaptive word-list memory test that matches test difficulty to user performance.
Maximum learning span is total number of words recognized.
|
Baseline, 2 years
|
|
Change in processing speed measure
Time Frame: Baseline, 2 years
|
Measured using the Mayo Test Drive (MTD):Test Development through Rapid Iteration, Validation and Expansion.
A web-based platform for remote self-administered cognitive assessment that uses a symbols test to measure processing speed reported in average completion time (seconds).
|
Baseline, 2 years
|
|
Ischemic stroke or systemic embolism events
Time Frame: 2 years
|
Number of ischemic stroke or systemic embolism events
|
2 years
|
|
Major bleeding
Time Frame: 2 years
|
Number of major bleeding events
|
2 years
|
|
Mortality
Time Frame: 2 years
|
Number of participant deaths
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Xiaoxi Yao, PhD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22-011253
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.